


Product Details

Product name:	Anti-human B7-H1 / PD-L1 / CD274 (avelumab Biosimilar)	SKU:	BIO0061SM
Target Name:	B7-H1 / PD-L1 / CD274	Size:	1 mg/5 mg/20 mg
Target Uniprot:	Q9NZQ7	Concentration:	Lyophilized
Clone#:	avelumab	Isotype:	Human IgG1
Reactivity:	Human, Mouse, Rat, Cynomolgus, Rabbit, Dog	Calculated M.W.:	150 kDa
Application:	ELISA, Bioactivity: FACS, Functional assay, Research in vivo	Endotoxin:	<0.001 EU/ug
Formulation:	0.1M Pro, 20mM Arg, pH5.0	Conjugation:	None
Storage:	For long term storage, the produce should be stored at -20° C or lower.	Expression System:	CHO
Reconstitution:	Dissolve with sterile ddH2O	Purification:	Protein A


Data

Purity:SDS-PAGE




Anti-B7-H1 / PD-L1 / CD274 (avelumab) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.

Purity:SEC-HPLC




The purity of Anti-B7-H1 / PD-L1 / CD274(avelumab) is 98.22%, determined by SEC-HPLC.

Bioactivity:ELISA



Immobilized human PD-L1 FC at 2 ug/mL can bind Anti-B7-H1 / PD-L1 / CD274 (avelumab), EC50=0.03725 ug/mL.

Research in vivo



Avelumab inhibited the tumor growth of MC38 on hLAG3 mice. The result showed significant anti-tumor effects, with a tumor inhibition rate (TGI) of 32.6% at 1 mpk at D28.